Safety and efficacy of 6% hydroxyethyl starch in patients undergoing major surgery

医学 羟乙基淀粉 麻醉 外科 随机对照试验 不利影响 临床试验 并发症 梅德林 回顾性队列研究
作者
Wolfgang Bühre,Óscar Díaz‐Cambronero,Simon Schaefer,Martin Nováček,Marina Soro Domingo,Björn Stessel,Aurelio Rodríguez,Torsten Richter,Georg Rohe,Bernard Cholley,Matthias Gruenewald,Gerhardus J.A.J.M. Kuiper,Samir Jaber,Dianne de Korte,Javier Belda,Marcelo Gama de Abreu,Robert Baronica,Thomas Scheeren,Carlos Ferrando-Ortolá,Wojciech Szczeklik
出处
期刊:European Journal of Anaesthesiology [Lippincott Williams & Wilkins]
卷期号:43 (1): 1-10 被引量:9
标识
DOI:10.1097/eja.0000000000002307
摘要

BACKGROUND: Hydroxyethyl starch (HES) is often used for maintaining vascular volume during major surgery. Long-term high-dose HES in septic patients promotes renal injury, whereas meta-analyses of current HES products in surgical patients do not show such effects. OBJECTIVE: We studied if the peri-operative use of HES is noninferior to crystalloids in terms of acute kidney injury. Secondary outcome was the noninferiority of HES on worsening of renal injury and/or the incidence of a composite endpoint of major complications and mortality until postoperative day 90. DESIGN: Randomised double-blind trial in patients undergoing elective abdominal surgery with expected blood loss at least 500 ml. SETTING: Multicentre trial at 53 study sites in 10 European countries. PATIENTS: One thousand nine hundred and eighty-five (HES 977, crystalloid-only 981) patients aged 40 to 85 years with ASA status II-III. INTERVENTION: Either 6% HES 130/0.4 or a crystalloid solution. Dosing was guided by mean arterial pressure and/or routine haemodynamic variables. MAIN OUTCOME MEASURE: Change from pre-operative to lowest cystatin C-based eGFR during the first 3 postoperative days. Key secondary outcome was a composite endpoint of mortality and major postoperative complications after 90 days. RESULTS: Mean change in eGFR from baseline to minimum was -3.4 ± 17.7 ml min -1 1.73 m -2 in HES patients and -1.0 ± 17.1 ml min -1 1.73 m -2 in crystalloid-only patients ( P < 0.001 for noninferiority). The key secondary endpoint occurred in 35% of patients in each group. There were no clinically relevant differences in any safety endpoint including 90-day renal function. Any cause mortality-difference until the end of 1-year follow-up was not significantly different (8.6% in HES and 10.1% in crystalloid patients). CONCLUSION: Peri-operative use of HES was noninferior to crystalloids in short-term renal function or a composite of mortality and major complications at 90 days. PHOENICS provides robust evidence that peri-operative in-label use of HES is well tolerated. TRIAL REGISTRATION AND FUNDING: EudraCT no. 2016-002162-30, clinicaltrials.gov ID NCT03278548.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研小菜鸟完成签到,获得积分10
1秒前
淡然一笑发布了新的文献求助10
1秒前
钺港完成签到 ,获得积分10
2秒前
2秒前
2秒前
trx发布了新的文献求助10
2秒前
田様的应助被科研通管家采纳,获得10
2秒前
SGQT完成签到 ,获得积分10
2秒前
香蕉觅云的应助被科研通管家采纳,获得10
2秒前
2秒前
彭于晏的应助被科研通管家采纳,获得10
3秒前
李健的应助被科研通管家采纳,获得10
3秒前
黄健丰发布了新的文献求助10
3秒前
3秒前
脑洞疼的应助被科研通管家采纳,获得10
3秒前
勤奋一一的应助被科研通管家采纳,获得10
3秒前
慢慢来了谢谢完成签到,获得积分10
3秒前
勤奋一一的应助被科研通管家采纳,获得10
3秒前
丘比特的应助被科研通管家采纳,获得10
3秒前
bkagyin的应助被科研通管家采纳,获得10
3秒前
无极微光的应助被科研通管家采纳,获得20
4秒前
脑洞疼的应助被科研通管家采纳,获得10
4秒前
syvshc的应助被科研通管家采纳,获得10
4秒前
酷波er的应助被Tnapo采纳,获得10
4秒前
4秒前
桐桐的应助被科研通管家采纳,获得10
4秒前
下载发布了新的文献求助10
4秒前
顾矜的应助被科研通管家采纳,获得10
4秒前
张张完成签到 ,获得积分10
4秒前
4秒前
sci01完成签到 ,获得积分10
4秒前
zyy发布了新的文献求助30
4秒前
boomilkan完成签到 ,获得积分10
5秒前
5秒前
Walker完成签到,获得积分10
5秒前
cwy发布了新的文献求助50
5秒前
夜幕完成签到,获得积分10
6秒前
苏邑发布了新的文献求助10
6秒前
赘婿的应助被酷酷班采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181379
求助须知:如何正确求助?哪些是违规求助? 9571317
关于积分的说明 21817457
捐赠科研通 7777820
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479523